title: BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
authors.affiliation: Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
authors.forename: C
authors.initials: C
authors.lastname: Fair
authors.affiliation: Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
authors.forename: R
authors.initials: R
authors.lastname: Shanley
authors.affiliation: Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
authors.forename: J
authors.initials: J
authors.lastname: Rogosheske
authors.affiliation: Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
authors.forename: A
authors.initials: A
authors.lastname: Lazaryan
authors.affiliation: Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
authors.forename: B
authors.initials: B
authors.lastname: McClune
authors.affiliation: Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
authors.forename: C G
authors.initials: CG
authors.lastname: Brunstein
authors.affiliation: Blood and Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
authors.forename: V
authors.initials: V
authors.lastname: Bachanova
mesh_terms: D000328:Adult; D000368:Aged; D064591:Allografts; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009765:Obesity; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D019172:Transplantation Conditioning
chemical_list: D003561:Cytarabine; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine